Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Increase in Short Interest

Key Points

• Bavarian Nordic experienced a 100% increase in short interest in July, with the total reaching 200 shares by the end of the month.
• The stock traded at $12.37 as of the latest market data, having a market capitalization of $2.93 billion and a PE ratio of 15.46.
• The company specializes in developing and commercializing life-saving vaccines, including those for smallpox, monkeypox, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 200 shares, agrowthof100.0% from the July 15th total of 100 shares. Based on an average daily volume of 38,100 shares, the days-to-cover ratio is presently 0.0 days. Approximately0.0% of the shares of the stock are sold short. Approximately0.0% of the shares of the stock are sold short. Based on an average daily volume of 38,100 shares, the days-to-cover ratio is presently 0.0 days.

Bavarian Nordic Stock Up 1.1%

BVNRY stock traded up $0.1320 during midday trading on Friday, hitting $12.4370. The company's stock had a trading volume of 1,558 shares, compared to its average volume of 7,863. Bavarian Nordic has a 12 month low of $6.5950 and a 12 month high of $13.99. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of 15.55 and a beta of 1.36. The company has a 50 day moving average of $10.44 and a two-hundred day moving average of $8.84.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last posted its quarterly earnings results on Friday, August 22nd. The company reported $0.23 earnings per share for the quarter. Bavarian Nordic had a return on equity of 11.89% and a net margin of 21.11%. On average, analysts anticipate that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.